Rocaltrol (calcitriol) is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body. Rocaltrol is available as capsules containing 0.25 mcg or 0.5 mcg calcitriol.
Rocaltrol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism.
Rocaltrol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, Rocaltrol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization.
Rocaltrol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism.
Published Studies Related to Rocaltrol (Calcitriol)
Association of higher plasma vitamin D binding protein and lower free calcitriol
levels with tenofovir disoproxil fumarate use and plasma and intracellular
tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? 
Tenofovir disoproxil fumarate (TDF) causes bone, endocrine, and renal changes by
an unknown mechanism(s)... Separate pharmacokinetic properties may be
associated with distinct TDF toxicities: tenofovir with parathyroid hormone and
altered calcium balance and tenofovir diphosphate with hypophosphatemia and FGF23
Oral Calcitriol for Reduction of Proteinuria in Patients With IgA Nephropathy: A Randomized Controlled Trial. [2011.10.21]
BACKGROUND: Vitamin D has shown efficacy in the reduction of proteinuria in patients with chronic kidney disease. This study aimed to determine the effect of calcitriol on urinary protein excretion in patients with immunoglobulin A (IgA) nephropathy... CONCLUSIONS: The addition of calcitriol to a renin-angiotensin system inhibitor resulted in a safe decrease in proteinuria in patients with IgA nephropathy. Copyright (c) 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. [2011.06.01]
PURPOSE: To compare the efficacy and safety of docetaxel plus high-dose calcitriol (DN-101) to docetaxel plus prednisone in an open-label phase III trial... CONCLUSION: ASCENT treatment was associated with shorter survival than the control. This difference might be due to either weekly docetaxel dosing, which, in a prior study, showed a trend toward inferior survival compared with an every-3-weeks regimen, or DN-101 therapy.
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. [2011.05]
BACKGROUND: Lanthanum carbonate and sevelamer carbonate are non-calcium-based phosphate binders used to manage hyperphosphataemia in patients with chronic kidney disease (CKD). Patients with CKD may require intravenous or oral active vitamin D. We investigated the effects of lanthanum carbonate and sevelamer carbonate on the bioavailability of oral calcitriol... CONCLUSIONS: Sevelamer carbonate significantly reduces serum concentrations of exogenous calcitriol when administered concomitantly with oral calcitriol, whereas lanthanum carbonate has no significant effect. This should be considered when treating CKD patients who require phosphate binders and oral vitamin D.
Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. [2011.03]
AIM: Calcitriol and alfacalcidol are used extensively for the treatment of secondary hyperparathyroidism. Unfortunately, there is limited published data comparing the efficacy and tolerability of both active vitamin D sterols. This study was undertaken to determine whether calcitriol provides a therapeutic advantage to alfacalcidol... CONCLUSION: Alfacalcidol can be used to control secondary hyperparathyroidism at doses of 1.5-2.0 times that of calcitriol. The two drugs are equally efficacious and lead to similar changes in calcium and phosphorus. (c) 2011 The Authors. Nephrology (c) 2011 Asian Pacific Society of Nephrology.
Clinical Trials Related to Rocaltrol (Calcitriol)
The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers [Completed]
Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery [Active, not recruiting]
This phase I trial studies the side effects and best dose of calcitriol when given with
cisplatin and gemcitabine hydrochloride in treating patients with advanced solid tumors that
cannot be removed by surgery. Drugs used in chemotherapy, such as cisplatin and gemcitabine
hydrochloride, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Calcitriol may stop the growth of tumor cells
by blocking blood flow to the tumor. Calcitriol may also help cisplatin and gemcitabine
hydrochloride kill more tumor cells by making them more sensitive to the drug.
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer [Active, not recruiting]
This phase I/II trial studies the side effects and best dose of calcitriol when given in
combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in
treating patients with prostate cancer. Calcitriol may help prostate cancer cells become
more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic
hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the
drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a
better treatment for prostate cancer.
Vitamin D and Coronary Calcification Study [Recruiting]
Patients with chronic kidney disease (CKD) have a higher mortality rate than the general
population, with cardiovascular disease (CVD) accounting for approximately 50% of deaths.
Vascular calcification is a common finding in patients with CKD. Furthermore, patients with
CKD develop secondary hyperparathyroidism, partly because of a decrease of calcitriol
synthesis on the kidney. Treatment of secondary hyperparathyroidism includes use of
activated vitamin D including calcitriol and paricalcitol. Recent evidence in dialysis
patients suggest an improved survival in patients using paricalcitol compared to calcitriol.
Studies in uremic rats suggests that there are differential effects of calcitriol and
paricalcitol in expression of markers of soft-tissue calcification independent of
calcium-phosphorus product. Calcitriol increased calcification of vascular smooth muscle
cells cultured in calcification media. There was also significant increase in pulse pressure
in animals treated with calcitriol.
The investigators hypothesize that these different forms of vitamin D may have differential
effects in vascular calcification progression in CKD patients.
Calcitriol in Preventing Lung Cancer in High-Risk Patients [Recruiting]
This pilot clinical trial studies the side effects of calcitriol in preventing lung cancer
in high risk patients. Chemoprevention is the use of certain drugs to keep cancer from
forming. The use of calcitriol may keep cancer from forming in patients with high risk for
Reports of Suspected Rocaltrol (Calcitriol) Side Effects
Decreased Appetite (6),
Drug Interaction (5),
Cardiac Failure (5),
Hypereosinophilic Syndrome (4),
Renal Failure (4),
Renal Impairment (4),
Productive Cough (3),
Pain (3), more >>
Page last updated: 2014-11-30